Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells

Blood (2018) 132 (Supplement 1): 4246.

https://doi.org/10.1182/blood-2018-99-119974

Published: 2018

Journal Articles

Osteonecrosis of the Femoral Head in Sickle Cell Disease: Prevalence, Comorbidities and Surgical Outcomes in California

Oyebimpe O Adesina, MD, Ann M Brunson, MS, Jason R. Gotlib, MD, Theresa Keegan, PhD MS, Ted Wun, MD

Blood (2016) 128 (22): 2489.

https://doi.org/10.1182/blood.V128.22.2489.2489

Published: 2016

Journal Articles

Identification of a Novel MPL Loss of Function Mutation in a Patient with Cyclic Thrombocytopenia and Characterization of This Syndrome

Haiyu Zhang, PhD, Yu Hou, MD, Rondeep S. Brar, MD, Bing Zhang, MD MS, Zhenping Chen, PhD MD, Parveen Abidi, PhD, Jing Jin, MD, Jason R. Gotlib, MD, James L. Zehnder, MD

Blood (2016) 128 (22): 1376.

https://doi.org/10.1182/blood.V128.22.1376.1376

Published: 2016

Journal Articles

A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF)

Srdan Verstovsek, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Jason R. Gotlib, MD, Ruben A. Mesa, MD, Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francisco Cervantes, MD PhD, William Sun, PhD, Jessy Gao, MA, Touchuan Dong, Ahmad Naim, MD, Prashanth Gopalakrishna, MBBS, MRCS, Claire N. Harrison, DM, FRCP, FRCPath

Blood (2016) 128 (22): 3110.

https://doi.org/10.1182/blood.V128.22.3110.3110

Published: 2016

Journal Articles

Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials

Vikas Gupta, MD FRCP, FRCPath, Srdan Verstovsek, MD PhD, Ronald Paquette, MD, Jason R. Gotlib, MD, Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francisco Cervantes, MD PhD, William Sun, PhD, Jessy Gao, MA, Peter Langmuir, MD, Prashanth Gopalakrishna, MBBS, MRCS, Claire N. Harrison, DM, FRCP, FRCPath

Blood (2016) 128 (22): 3118.

https://doi.org/10.1182/blood.V128.22.3118.3118

Published: 2016

Journal Articles

A Predictive Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers and a Large Industry-Based Cohort

Kamal Menghrajani, MD, Philip S. Boonstra, PhD, Cecelia Perkins, MPH, Krisstina L. Gowin, DO, Ruben A. Mesa, MD, Jason R. Gotlib, MD, Moshe Talpaz, MD

Blood (2016) 128 (22): 4270.

https://doi.org/10.1182/blood.V128.22.4270.4270

Published: 2016

Journal Articles

Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, William Sun, PhD, Ahmad Naim, MD, Smitha Svaraman, PhD, Jessy Gao, MA, Jason R. Gotlib, MD, Vikas Gupta, MD FRCP, FRCPath, Kim-Hien Dao, DO, PhD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 1949.

https://doi.org/10.1182/blood.V128.22.1949.1949

Published: 2016

Journal Articles

Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry)

Blood (2016) 128 (22): 396.

https://doi.org/10.1182/blood.V128.22.396.396

Published: 2016

Journal Articles

Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia

Blood (2016) 128 (22): 4245.

https://doi.org/10.1182/blood.V128.22.4245.4245

Published: 2016

Journal Articles

Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results

Srdan Verstovsek, MD PhD, Ruben A. Mesa, MD, Lynda M Foltz, MD, Vikas Gupta, MD FRCP, FRCPath, John O Mascarenhas, MD MS, Ellen K. Ritchie, MD, Ronald Hoffman, MD, Richard T. Silver, MD, Marina Kremyanskaya, MDPhD, Olga Pozdnyakova, MD PhD, Robert P Hasserjian, MD, Elizabeth Trehu, MD, Hagop M. Kantarjian, MD, Jason R. Gotlib, MD

Blood (2014) 124 (21): 713.

https://doi.org/10.1182/blood.V124.21.713.713

Published: 2014

Journal Articles

A New Prognostic Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers

Menghrajani Kamal, MD, Philip S. Boonstra, PhD, Alissa A. Weber, MD, Cecelia Perkins, MPH, Krisstina L. Gowin, DO, Huong (Marie) Nguyen, MD, Ruben Mesa, MD, Jason R. Gotlib, MD, Moshe Talpaz

Blood (2014) 124 (21): 1842.

https://doi.org/10.1182/blood.V124.21.1842.1842

Published: 2014

Journal Articles

Next Generation Sequencing to Delineate the Mutational Landscape of Chronic Myelomonocytic Leukemia (CMML): Novel Disease Genes and Correlations with Survival

Clinton C. Mason, PhD, Jamshid S. Khorashad, MD PhD, Srinivas K. Tantravahi, MD, Todd W. Kelley, MD, Anthony D. Pomicter, M.S., Anthony J. Iovino, Kimberly R. Reynolds, M.S., Anna M. Eiring, PhD, Matthew S. Zabriskie, BS, Zev Kronenberg, Jeffrey W. Tyner, Brian Dalley, PhD, Kim-Hien T. Dao, DO,PhD, Thomas O'Hare, PhD, Mark Yandell, PhD, Brian J. Druker, Jason R. Gotlib, MD, Michael W. Deininger

Blood (2014) 124 (21): 4637.

https://doi.org/10.1182/blood.V124.21.4637.4637

Published: 2014

Journal Articles

Update of a Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies

Edward D. Ball, MD, Bruno C. Medeiros, MD, Larissa Balaian, PhD, Tracy Roque, Sue Corringham, Richa Rajwanshi, Steven Coutre, Jason R Gotlib, MD, MS, Asad Bashey, MD, PhD, Karen Messer

Blood (2010) 116 (21): 3286.

https://doi.org/10.1182/blood.V116.21.3286.3286

Published: 2010

Journal Articles

Sample Cryopreservation Does Not Affect Functional Read Outs In SCNP Assays: Implications for Biomarker Development

Alessandra Cesano, MD, Jason R Gotlib, MD, MS, Norman J. Lacayo, MD, Santosh Putta, Ph.D., Alan Lackey, MS, Urte Gayko, Ph.D., Steven M. Kornblau, MD

Blood (2010) 116 (21): 4843.

https://doi.org/10.1182/blood.V116.21.4843.4843

Published: 2010

Journal Articles

Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly, Disease-Related Symptoms, and JAK2 V617F Allele Burden

Animesh Pardanani, MBBS, PhD, Jason R Gotlib, MD, MS, Catriona Jamieson, MD, PhD, Jorge E. Cortes, MD, Moshe Talpaz, MD, Richard M Stone, M.D., Michael H Silverman, MD, FACP, Jolene Shorr, D. Gary Gilliland, MD, PhD, Ayalew Tefferi, MD

Blood (2010) 116 (21): 459.

https://doi.org/10.1182/blood.V116.21.459.459

Published: 2010

Journal Articles

A Novel Missense Mutation In An MDS Patient and Effects on TET2 mRNA Expression and Clinical Outcomes

Daniel A Pollyea, MD, Aparna Raval, PhD, Brenda Kusler, Jason R Gotlib, MD, MS, Ash A. Alizadeh, MD, PhD, Beverly S. Mitchell, MD

Blood (2010) 116 (21): 1889.

https://doi.org/10.1182/blood.V116.21.1889.1889

Published: 2010

Journal Articles

Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS).

Holbrook E Kohrt, MD, Samit Patel, Michelle Ho, Terri Owen, Ravindra Majeti, MD, PhD, Jason R. Gotlib, MD, Steve Coutre, MD, Bruno C. Medeiros, MD, Ash A Alizadeh, MD, PhD

Blood (2009) 114 (22): 1617.

https://doi.org/10.1182/blood.V114.22.1617.1617

Published: 2009

Journal Articles

AML Patients with Monosomal Karyotype Are Characterized by Absence of NPM1 and FLT3 Mutations and Worse Clinical Outcome.

Mahesh Seetharam, MD, Olga K Weinberg, MD, Li Ren, MS, Lisa Ma, MS, Katie Seo, MS, James L. Zehnder, MD, Jason R Gotlib, MD, MS, Daniel A. Arber, MD

Blood (2009) 114 (22): 2638.

https://doi.org/10.1182/blood.V114.22.2638.2638

Published: 2009

Journal Articles

RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies.

Jeffrey W Tyner, PhD, Marc Loriaux, MD, PhD, Stephanie G Willis, Bill H Chang, MD, PhD, Vincent T Bicocca, Stephen T Oh, MD, PhD, Iris H.I.M. Hollink, MD, Stefanie Segers, Monique L. DenBoer, MSc, PhD, Marry M van den Heuvel-Eibrink, MD, PhD, C. Michel Zwaan, MD, PhD, Jason R Gotlib, MD, MS, Michael Deininger, MD, PhD, Brian J. Druker, MD

Blood (2009) 114 (22): 3978.

https://doi.org/10.1182/blood.V114.22.3978.3978

Published: 2009

Journal Articles

Development of a Small-Molecule Inhibitor Screen to Rapidly Identify Key Signaling Pathways in Leukemogenesis.

Jeffrey W Tyner, PhD, Luke Fletcher, Wayne Yang, Stephen T Oh, MD, PhD, Jason R. Gotlib, MD, Michael WN Deininger, MD, Brian J. Druker, MD, Marc Loriaux, MD, PhD

Blood (2009) 114 (22): 708.

https://doi.org/10.1182/blood.V114.22.708.708

Published: 2009

NARROW

Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells

Osteonecrosis of the Femoral Head in Sickle Cell Disease: Prevalence, Comorbidities and Surgical Outcomes in California

Identification of a Novel MPL Loss of Function Mutation in a Patient with Cyclic Thrombocytopenia and Characterization of This Syndrome

A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF)

Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials

A Predictive Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers and a Large Industry-Based Cohort

Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study

Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry)

Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia

Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results

A New Prognostic Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers

Next Generation Sequencing to Delineate the Mutational Landscape of Chronic Myelomonocytic Leukemia (CMML): Novel Disease Genes and Correlations with Survival

Update of a Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies

Sample Cryopreservation Does Not Affect Functional Read Outs In SCNP Assays: Implications for Biomarker Development

Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly, Disease-Related Symptoms, and JAK2 V617F Allele Burden

A Novel Missense Mutation In An MDS Patient and Effects on TET2 mRNA Expression and Clinical Outcomes

Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS).

AML Patients with Monosomal Karyotype Are Characterized by Absence of NPM1 and FLT3 Mutations and Worse Clinical Outcome.

RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies.

Development of a Small-Molecule Inhibitor Screen to Rapidly Identify Key Signaling Pathways in Leukemogenesis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only